Huron Gastroenterology Associates

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis3 trials
• Fatty liver disease (MASLD/MASH)2 trials
• Crohn's disease1 trial
• Eosinophilic oesophagitis1 trial
• Liver cirrhosis1 trial
• Obesity1 trial

Phase

• Phase 34 trials
• Phase 22 trials

Status

• Completed4 trials
• Active, not recruiting1 trial
• Not yet recruiting1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• Boehringer Ingelheim1 trial
• Gilead Sciences1 trial
• Phathom Pharmaceuticals, Inc.1 trial
• Takeda1 trial

Running trials

• Not yet recruiting

  ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

  NCT07850063· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Active, not recruiting

  A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

  NCT06851559· Phase 2· Phathom Pharmaceuticals, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Takeda· Source